L-Carnitine Administration in Early Sepsis

Septic Shock Clinical Trial

Official title: L-Carnitine Administration in Early Sepsis

Status Terminated

Clinical Trial Summary

Sepsis is a severe and overwhelming response to an infection in the body. Over 750,000 patients in the United States develop sepsis every year. As sepsis becomes progressively more severe, a patient's blood pressure drops to dangerous levels and the body cannot pump oxygen to the rest of the body, which is necessary for normal cell function. This is called septic shock. When someone develops septic shock, it is very common for the smallest blood vessels in the body called the microcirculation to clog, like a highway during rush hour. Even with the best medical care, more than one in three patients with septic shock will die.

The major goal of this study is to test if intravenous replacement of a naturally occurring nutrient that is lost by the body during sepsis called L-carnitine can reduce how sick a patient with sepsis becomes. In our study, some patients will receive L-carnitine and others will receive saline. We will measure markers determining severity of illness in both groups and compare them to see if L-carnitine helps patients get better faster. Based on research already conducted, we believe L-carnitine will improve blood flow in the microcirculation, delivering more oxygen to cells, and help the body get better. To test if this is true, we will directly look at the microcirculation under the tongue with a special magnifying camera that looks at red blood cells, and compare both groups.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Sepsis
• Septic Shock

• NCT number: NCT01193777
• Study type: Interventional
• Source: Wake Forest University Health Sciences
• Status: Terminated
• Phase: Phase 1
• Start date: September 2010
• Completion date: February 2012